StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
067630.KQ$3330.00+1.52%
Fair $3330.00+0.0%

067630.KQ

HLB Life Science Co., Ltd.

Unknown / UnknownKOSDAQ

$3330.00

+50.00 (+1.52%)

Fairly Valued+0.0%Fair Value $3330.00Fund rank 28/100 · Data gapFallback financials|
SA 10/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 21%

FCF escenarios

weak_data · normalized FCF $-48.9B · quality 59.7/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

10/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -33.6%, below the 5% threshold
Thesis & Journal · 067630.KQLocal privado en este navegador · HLB Life Science Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$405.8B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-33.6%

↓

Gross Margin

-1.1%

↓

Debt/Equity

0.54

↑
52-Week Range$3330
$3105$6330

TradingView lightweight chart

067630.KQ price, volumen y niveles de valoración

Último $3,330Periodo +190.9%
Fair value: $3,330

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-22.8%

FCF CAGR

—

FCF margin

-106.8%

FCF / Net income

0.49x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $45.75B · net income $-99.79B · FCF $-48.88B

2022-FY → 2025-FY

Gross margin

-1.1%+2.0% pts

Operating margin

-45.9%-25.9% pts

Net margin

-218.1%-163.6% pts

FCF margin

-106.8%-65.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$45.75B$45.75B$32.77B$97.99B$99.59B
Net Income$-99.79B$-99.79B$6.14B$-5.98B$-54.28B
EBITDA$-83.58B$-83.58B$26.35B$22.84B$-45.75B
EPS-819.00-819.0055.00-54.79-533.76
Gross Margin-1.1%-1.1%-10.0%-0.8%-3.1%
Operating Margin-45.9%-45.9%-60.9%-25.0%-20.0%
Net Margin-218.1%-218.1%18.7%-6.1%-54.5%
Balance Sheet
Debt/Equity0.540.540.310.720.63
Cash Flow
Free Cash Flow$-48.88B$-48.88B$-59.47B$-31.54B$-41.40B
Returns
ROE-33.6%-33.6%1.5%-2.6%-23.1%
Valuation
P/E——188.55——
EV/EBITDA——46.6155.94—
P/B1.361.362.914.894.77
Growth & Yield
Revenue Growth39.6%39.6%-66.6%-1.6%—
EPS Growth-1589.1%-1589.1%200.4%89.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -44.6%

Total return

-44.6%

Start / end P/E

n/dx → n/dx

EPS bridge

55.00 → -819.00

Residual

-44.6%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-44.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.